Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
camrelizumab + rh-endostatin
- Development stage
- Phase 2
- Lead developer
- Hengrui Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
camrelizumab + rh-endostatin is a combination therapy for advanced non-small cell lung cancer (NSCLC). Camrelizumab is an anti-PD-1 monoclonal antibody that blocks the PD-1/PD-L1 immune checkpoint, enhancing T-cell-mediated antitumor immunity. Rh-endostatin (recombinant human endostatin) is an antiangiogenic drug that inhibits tumor angiogenesis by targeting vascular endothelial cells, promoting vascular normalization and improving the tumor immune microenvironment. The combination has shown promising efficacy and safety in clinical studies for advanced NSCLC.
- Other names
- camrelizumab plus rh-endostatinrh-endostatin plus camrelizumab
02
Targets
Beyond the preview
Go deeper on camrelizumab + rh-endostatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on camrelizumab + rh-endostatin.